|
|
Articles Index/Vaccinations - When?, Why?, How?
Posted 02/01/11
|
|
There is a growing debate about vaccines and among the most frequently asked questions are how often should you vaccinate your dog? What 'shots' can be given in combination and which should be saparated? Are vaccines safe?
What is the ‘Rabies Challenge’ and why is it important? What’s with the new Lyme vaccine? How do I know if what my veterinarian suggests is good for my dog? Is it OK to ask questions?
ANTA is pleased that we have two leading researchers from the Cornell University College of Veterinary Medicine Baker Institute for Animal Health to answer some of those questions.
Colin Parrish, PhD is the John M. Olin Professor of Virology. In his laboratory he studies viral diseases of dogs and cats. The lab seeks to find how viruses function, how they infect cells, and how the immune response of a host controls infection. A major aim is to develop better and more effective methods for vaccinating dogs and cats against viral infection.
Among the work being done by Parrish is the examination of the canine influenza virus (CIV) that first emerged in greyhounds in Florida around the year 2000 and is now established in the domestic dog population in many parts of the US.
John S. Parker, BVMS, PhD is associate professor of virology and the recipient of the 2007 “Pfizer Animal Health Award for Research Excellence.”
In his lab he is studying the assembly, function, and cytopathic effects
of large virus-derived structures called viral factories. These factories
are the likely sites of viral transcription, new virus particle assembly
and viral replication.
The Baker Institute
The Baker Institute has a long history of research excellence in veterinary
medicine. Among its milestone discoveries affecting our dogs are:
discovery of carrier state and first vaccine for infectious canine hepatitis;
first combined vaccines for dogs; isolation and characterization of Brucella
canis; definition of the pathogenesis of canine distemper; isolation of
canine parvovirus-type 2 (CPV-2) and development of first vaccines for CPV-2.
ANTIC, September, 2010
Back to Articles Index
Back to Home Page
